Hormones Matter TM

PR: Lucine Biotech Featured in Gigaom

July 23, 2012  |  Lisbeth Prifogle


Most people hear think that Las Vegas is a synonym for lights, glamor, casinos and/or gambling, not the next Silicon Valley. Thanks to Zappos CEO Tony Hsieh’s Downtown Project and the entrepreneurial spirit and dedication of locals, Vegas will soon have new synonyms that will help tackle the high unemployment rates due to the recession. For more information on the growing tech scene, click here.

One of those tech companies rising like a phoenix is Lucine Biotech. As Gigaom reports in their article, 5 Las Vegas Startups You Need to Know:

“The vision of a Silicon Strip is coming along nicely. Just about a year into a concerted effort to build a technology scene in Las Vegas, startups of all types are already forming in Las Vegas and moving to the city. Here are five of the city’s most-promising startups that are actually doing business:

2. Lucine Biotechnology

Lucine Biotechnology is a small, still-unfunded biotech startup that aims to fundamentally change healthcare for women. The current state of affairs, according to Founder and CEO Chandler Marrs, is that it’s pretty much a crapshoot as to whether medicines or treatments will work on women because relatively little attention is paid to their very real hormonal issues. Often times, women end up serving as “their own experiments,” she said.

The idea behind Lucine is to be a version of PatientsLikeMe focused specifically on women. Women join the social platform (which will launch in October) and share everything of relevance about their health situations — age, race, medicines, supplements, hormone levels (Lucine will actually conduct testing), symptoms, etc. Members can learn from others like them what treatments are working or how common side effects really are, while Lucine analyzes their data to draw correlations among the myriad variables.

Given a large-enough user base, platforms like Lucine can do crowdsourced medical studies faster, cheaper and with more data points than can traditional corporate or academic researchers. Although, Marrs acknowledges, that’s just the first step. Hopefully, the next step is that Lucine’s findings will provide enough data to spur scientifically validated studies that change how doctors, pharmaceutical companies and insurance companies approach women’s health. With enough data, Marrs said, “I anticipate we’ll find patterns no one has thought to look at.”

For more information and to read the full article, click here.